FDA approves first pill-based postpartum depression treatment.

A pill-based treatment for postpartum depression has been approved by the U.S. Food and Drug Administration (FDA), the New York Times and AFP reported on Thursday.

The new antidepressant, zuranolone, co-developed by U.S. pharmaceutical companies Sage and Biogen, will be available under the name Zurzuvae within the year.

While zulesso, the only FDA-approved treatment for postpartum depression before zuranolone, is an intravenous drug that must be administered continuously for 60 hours, zuranolone comes in pill form and can be taken once a day for at least two weeks.

Zuranolone treats postpartum depression by using a neurosteroid to regulate gamma-aminobutyric acid, a neurotransmitter in the brain.

Postpartum depression, which occurs between four weeks and 12 months after giving birth, is characterized by symptoms of sadness, anxiety, and extreme fatigue.

In the United States, 카지노사이트넷 an estimated 500,000 women suffer from postpartum depression each year.